Cullinan Oncology Q3 2023 Investor Presentation

Cullinan Oncology is advancing clinical-stage oncology programs including zipalertinib (CLN-081/TAS6417) for NSCLC EGFR exon20 mutations and CLN-619, a MICA/B-stabilizing immunotherapy. The presentation highlights pivotal Phase 2b and Phase 3 trials, a co-development partnership with Taiho Oncology, and initial monotherapy efficacy data from lead programs.